Preliminary data from a Phase 1b dose escalation study of OP-1250, an oral CERAN, in combination with palbociclib in patients with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer

被引：0
|
作者：
Chan, Arlene
Day, Daphne
Hui, Rina
McCarthy, Nicole
Wilson, Rosalind
Faltaos, Demiana
Shaw, Morena
Murphy, Caitlin
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P3-07-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-15
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer
    Patel, Manish
    Alemany, Carlos
    Mitri, Zahi
    Makower, Della
    Borges, Virginia
    Sparano, Joseph
    Trinh Le
    Klein, Pamela
    Lawrence, Julia
    Kushner, Peter
    Faltaos, Demiana
    Harmon, Cyrus
    Myles, David
    Zujewski, JoAnne
    Hamilton, Erika
    CANCER RESEARCH, 2022, 82 (04)
  • [2] Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)
    Hamilton, E.
    Meisel, J.
    Alemany, C.
    Virginia, B.
    Lin, N.
    Wesolowski, R.
    Mathauda-Sahota, G.
    Makower, D.
    Lawrence, J.
    Faltaos, D.
    Mitri, Z.
    Sabanathan, D.
    Clark, D.
    Pluard, T.
    Hui, R.
    McCarthy, N.
    Patel, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S36 - S36
  • [3] A Phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients
    Chan, Arlene
    Day, Daphne
    Phuong Dinh
    Slancar, Michael
    Lombard, Janine
    Ganju, Vinod
    McCarthy, Nicole
    Wilson, Rosalind
    Faltaos, Demiana
    Mathauda-Sahota, Gurpreet
    Murphy, Caitlin
    CANCER RESEARCH, 2024, 84 (09)
  • [4] A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer
    Borges, Virginia F.
    Chan, Arlene
    Lin, Nancy U.
    Tonda, Margaret Eleanor
    Shilkrut, Mark
    Alemany, Carlos A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
    Lin, N. U.
    Borges, V. F.
    Patel, M. R.
    Okera, M.
    Meisel, J.
    Wesolowski, R.
    Pluard, T.
    Miller, K. D.
    McCarthy, N. J.
    Conlin, A. K.
    Mahtani, R.
    Sabanathan, D.
    McCann, K. E.
    Roesch, E.
    Mathauda-Sahota, G.
    Schroeder, J.
    Hamilton, E. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S338 - S338
  • [6] A phase 1/2 dose escalation and expansion study of OP-1250 in adults with advanced and/or metastatic hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer
    Alemany, Carlos
    Patel, Manish
    Mitri, Zahi
    Sparano, Joseph
    Borges, Virginia
    Makower, Della
    Klein, Pam
    Lawrence, Julia
    Le, Trinh
    Zujewski, Jo Anne
    Harmilton, Erika
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [7] A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib or alpelisib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced and/or metastatic breast cancer
    Borges, Virginia
    Alemany, Carlos
    Lin, Nancy
    Ma, Cynthia
    Tonda, Margaret
    Shaw, Morena
    Chan, Arlene
    CANCER RESEARCH, 2024, 84 (09)
  • [8] A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer
    Hamilton, Erika
    Alemany, Carlos
    Lin, Nancy U.
    Klein, Pamela M.
    Trinh Le
    Kushner, Peter J.
    Harmon, Cyrus
    Zujewski, Jo Anne
    Patel, Manish
    CANCER RESEARCH, 2021, 81 (04)
  • [9] Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
    Tolaney, Sara M.
    Beeram, Muralidhar
    Beck, J. Thaddeus
    Conlin, Alison
    Dees, E. Claire
    Puhalla, Shannon L.
    Rexer, Brent N.
    Burris, Howard A., III
    Jhaveri, Komal
    Helsten, Teresa
    Becerra, Carlos
    Kalinsky, Kevin
    Moore, Kathleen N.
    Manuel, Allison M.
    Lithio, Andrew
    Price, Gregory L.
    Chapman, Sonya C.
    Litchfield, Lacey M.
    Goetz, Matthew P.
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [10] A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer
    Shatsky, Rebecca A.
    Batra-Sharma, Hemali
    Helsten, Teresa
    Schwab, Richard B.
    Pittman, Emily I.
    Pu, Minya
    Weihe, Elizabeth
    Ghia, Emanuela M.
    Rassenti, Laura Z.
    Molinolo, Alfredo
    Cabrera, Betty
    Breitmeyer, James B.
    Widhopf II, George F.
    Messer, Karen
    Jamieson, Catriona
    Kipps, Thomas J.
    Parker, Barbara A.
    BREAST CANCER RESEARCH, 2024, 26 (01)
12345